Guiming Zhang

Dr. Guiming Zhang

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2023 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
TLTian Liu
Tian Liu
SHShangcong Han
Shangcong Han
YYYu Yao
Yu Yao
GZGuiming Zhang
Guiming Zhang
In recent years, the abnormal glucose metabolism of tumor cells has attracted increasing attention. Abnormal glucose metabolism is closely related to the occurrence and development of tumors. Monocarboxylate transporters (MCTs) transport the sugar metabolites lactic acid and pyruvate, which affect glucose metabolism and tumor progression in a variety of ways. Thus, research has recently focused on MCTs and their potential functions in cancer. The MCT superfamily consists of 14 members. MCT1 and MCT4 play a crucial role in the maintenance of intracellular pH in tumor cells by transporting monocarboxylic acids (such as lactate, pyruvate and butyrate). MCT1 and MCT4 are highly expressed in a variety of tumor cells and are involved the proliferation, invasion and migration of tumor cells, which are closely related to the prognosis of cancer. Because of their important functions in tumor cells, MCT1 and MCT4 have become potential targets for cancer treatment. In this review, we focus on the structure, function and regulation of MCT1 and MCT4 and discuss the developed inhibitors of MCT1 and MCT4 to provide more comprehensive information that might aid in the development of strategies targeting MCTs in cancer.

1 January 2018 in Journal of Cancer
Verified
Journal Article
Open access
GZGuiming Zhang
Guiming Zhang
YZYongjian Zhang
Yongjian Zhang
DDDahai Dong
Dahai Dong
FWFangming Wang
Fangming Wang
XMXiaocheng Ma
Xiaocheng Ma
LSLijiang Sun
Lijiang Sun
Background: Monocarboxylate transporter isoform 1 (MCT1) is an important molecule in mediating lactate transportation. Recent studies have shown an oncogenic role of MCT1 in cancer development.

29 July 2014 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
GZGuiming Zhang
Guiming Zhang
YZYao Zhu
Yao Zhu
DYDing Ye
Ding Ye
Metabolic syndrome (MS) is a cluster of metabolic abnormalities, which has been regarded as a pivotal risk factor for cardiovascular diseases. Recent studies focusing on the relationship between MS and cancer have recognized the significant role of MS on carcinogenesis. Likewise, growing evidence suggests that MS has a strong association with increased renal cell carcinoma (RCC) risk. This review outlines the link between MS and RCC, and some underlying mechanisms responsible for MS-associated RCC.

26 November 2018 in Disease Markers
Verified
Journal Article
Open access
PDF file
WLWen Liu
Wen Liu
ZZZhonghan Zhou
Zhonghan Zhou
DDDahai Dong
Dahai Dong
LSLijiang Sun
Lijiang Sun
GZGuiming Zhang
Guiming Zhang
Objectives. To identify the association between night shift work and the risk of various cancers with a comprehensive perspective and to explore sex differences in this association. Methods. We searched PubMed, Embase, and Web of Science for studies on the effect of night shift work on cancer, including case-control, cohort, and nested case-control studies. We computed risk estimates with 95% confidence intervals (CIs) in a random or fixed effects model and quantified heterogeneity using the I2 statistic. Subgroup, metaregression, and sensitivity analyses were performed to explore potential sources of heterogeneity. Contour-enhanced funnel plots and the trim and fill method were used together to analyze bias. Linear dose–response analysis was used to quantitatively estimate the accumulative effect of night shift work on the risk of cancer. Results. Fifty-eight studies were eligible for our meta-analysis, including 5,143,838 participants. In the random effects model, the pooled odds ratio (OR) of cancers was 1.15 (95% CI = 1.08–1.22, P<0.001; I2=76.2%). Night shift work increased the cancer risk in both men (OR = 1.14, 95% CI = 1.05–1.25, P=0.003) and women (OR = 1.12, 95% CI = 1.04–1.20, P=0.002). Subgroup analyses showed that night shift work positively increased the risk of breast (OR = 1.22, 95% CI = 1.08–1.38), prostate (OR = 1.26, 95% CI = 1.05–1.52), and digestive system (OR = 1.15, 95% CI = 1.01–1.32) cancers. For every 5 years of night shift work, the cancer risk increased by 3.2% (OR = 1.032, 95% CI = 1.013–1.051). Conclusion. This is the first meta-analysis identifying the positive association between night shift work and the risk of cancer and verifying that there is no sex difference in the effect of night shift work on cancer risk. Cancer risk increases with cumulative years of night shift work.

1 July 2021 in Asian Journal of Andrology
Verified
Journal Article
Open access
PDF file
WLWen Liu
Wen Liu
YYYu Yao
Yu Yao
XLXue Liu
Xue Liu
YLYong Liu
Yong Liu
GZGuiming Zhang
Guiming Zhang
This study aimed to identify the pathological outcomes and survival benefits of neoadjuvant hormone therapy (NHT) combined with radical prostatectomy (RP) and radiotherapy (RT) administered to patients with high-risk prostate cancer (HRPCa). We searched PubMed, Embase, and the Cochrane Library for studies comparing NHT plus RP or RT with RP or RT alone, administered to patients with HRPCa. We used a random-effects model to compute risk estimates with 95% confidence intervals (CIs) and quantified heterogeneity using the I2 statistic. Subgroup and sensitivity analyses were performed to identify potential sources of heterogeneity. We selected 16 studies. NHT before RP significantly decreased lymph node involvement (risk ratio [RR] = 0.69, 95% CI: 0.56–0.87) and increased the rates of pathological downstaging (RR = 2.62, 95% CI: 1.22–5.61) and organ-confinement (RR = 2.24, 95% CI: 1.54–3.25), but did not improve overall survival and biochemical progression-free survival (bPFS). The administration of NHT before RT to patients with HRPCa was associated with significant benefits for cancer-specific survival (hazard ratio [HR] = 0.51, 95% CI: 0.39–0.68), disease-free survival (HR = 0.51, 95% CI: 0.44–0.60), and bPFS (HR = 0.54, 95% CI: 0.46–0.64). Short-term NHT combined with RT administered to patients with HRPCa conferred significant improvements. Although the advantage of local control was observed when NHT was administered before RP, there was no significant survival benefit associated with HRPCa. Therefore, short-term NHT combined with RT is recommended for implementation in standard clinical practice but not for patients who undergo RP.

3 September 2019 in Disease Markers
Verified
Journal Article
Open access
PDF file
WLWen Liu
Wen Liu
LSLijiang Sun
Lijiang Sun
FGFengju Guan
Fengju Guan
FWFangming Wang
Fangming Wang
GZGuiming Zhang
Guiming Zhang
This study was performed to identify the prognostic impact of lymphovascular invasion (LVI) in patients with upper urinary tract urothelial carcinoma (UTUC) after radical nephroureterectomy (RNU). A systematic search in PubMed, Embase, and the Cochrane Library was performed to identify relevant studies. The outcomes of interest, including progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS), were extracted, and the pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were used for effect size estimation. Subgroup, metaregression, and sensitivity analyses were performed to explore potential origins of heterogeneity. Publication bias was estimated by Egger’s linear regression and funnel plot. Our meta-analysis included a total of 27 studies involving 17,453 patients. The pooled HRs were statistically significant for PFS (HR=1.73, 95%CI=1.41–2.11), CSS (HR=1.87, 95%CI=1.54–2.27), and OS (HR=1.56, 95%CI=1.29–1.87), with high heterogeneity (I2=77.8%, 70.3%, and 59.2%, respectively). Four studies explored the prognostic value of LVI in patients with advanced tumor stages (T3–T4). The fixed effects model (I2=33.9%) showed that the pooled HR was 1.64 (95%CI=1.35–1.99) for CSS. Egger’s plots showed no significant publication bias (PFS: P=0.443, CSS: P=0.096, and OS: P=0.894). Our meta-analysis demonstrated that LVI is a poor prognostic factor for UTUC and is strongly associated with disease recurrence, cancer-specific mortality, and overall mortality.